Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1)
Condition: Breast Neoplasms Intervention: Drug: DZD3969 Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials